Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Engineered NK Cells in Recurrent Grade 4 Astrocytoma
NCT04991870Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2023
- Primary completion
- Jan 2027
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CB-NK-TGF-betaR2 + NR3C1 in astrocytoma, glioblastoma (GBM) and Gliosarcoma (GS) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Dose-Limiting Toxicities at 28 days. Started Apr 2023; status: recruiting.
02
Drugs
CB-NK-TGF-betaR2 + NR3C1
03
Conditions
astrocytomaglioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT04991870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04991870.